[Viral safety in hemotherapy. Current aspects of hepatitis C and parvovirus B19 detection for plasma component therapy].
A major risk of plasma component therapy was the transmission of infectious diseases. Heat inactivation, TNBP/detergent- or beta-propiolactone/UV-treatment were introduced to reduce the risk of virus transmission, most notably those that cause hepatitis or AIDS. Therefore we discuss topical problems of virus inactivation, particularly for the recently discovered hepatitis C-virus and the well-known parvovirus B19.
Sibrowski
W
W
Abt. f. Transfusionsmedizin u. Transplantationsimmunologie, Universitäts-Krankenhaus Eppendorf, Hamburg.
Kühnl
P
P
D000914:Antibodies, Viral / Q000032:analysis; D001781:Blood Component Removal; D001798:Blood Proteins / Q000276:immunology; D001803:Blood Transfusion; D016174:Hepacivirus / Q000276:immunology / Q000302:isolation & purification*; D006526:Hepatitis C / Q000517:prevention & control / Q000635:transmission*; D006801:Humans; D010321:Parvoviridae / Q000276:immunology / Q000302:isolation & purification*; D010322:Parvoviridae Infections / Q000517:prevention & control / Q000635:transmission*; D012307:Risk Factors
D000914:Antibodies, Viral; D001798:Blood Proteins
Zur Problematik der Virussicherheit in der Hämotherapie. Aktuelle Aspekte des Hepatitis-C- und Parvovirus B19-Nachweises für die Plasmakomponententherapie.